Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer

Oxaliplatin is successfully used to eradicate micro-metastasis and improve survival, whereas the benefit of adjuvant chemotherapy in the early stages of colorectal cancer remains controversial. Inflammation plays a crucial role in colorectal cancer tumorigenesis. Inflammatory mechanisms are mediated...

ver descrição completa

Detalhes bibliográficos
Autores: Martinez-Bernabe, Toni, Oliver, Jordi, Sastre-Serra, Jorge, Pons, Daniel-Gabriel
Tipo de documento: artigo
Data de publicação:2023
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositório:Repisalud
Idioma:inglês
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23691
Acesso em linha:https://hdl.handle.net/20.500.12105/23691
Access Level:Acceso aberto
Palavra-chave:Neoplasias Colorrectales
Humanos
Citocinas
Protocolos de Quimioterapia Combinada Antineoplásica
Oxaliplatino
Cytokines
Colorectal Neoplasms
Humans
Oxaliplatin
Antineoplastic Combined Chemotherapy Protocols
id ES_9f6c11dde37c2b4cf493fd1e4e01845c
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/23691
network_acronym_str ES
network_name_str España
repository_id_str
spelling Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal CancerMartinez-Bernabe, ToniOliver, JordiSastre-Serra, JorgePons, Daniel-GabrielNeoplasias ColorrectalesHumanosCitocinasProtocolos de Quimioterapia Combinada AntineoplásicaOxaliplatinoCytokinesColorectal NeoplasmsHumansOxaliplatinAntineoplastic Combined Chemotherapy ProtocolsOxaliplatin is successfully used to eradicate micro-metastasis and improve survival, whereas the benefit of adjuvant chemotherapy in the early stages of colorectal cancer remains controversial. Inflammation plays a crucial role in colorectal cancer tumorigenesis. Inflammatory mechanisms are mediated by different immune cells through different cytokines, chemokines, and other proinflammatory molecules that trigger cell progression, an increase of cancer stem cell population, hyperplasia, and metastasis. This study focuses on the analysis of the oxaliplatin effect on tumourspheres formation efficiency, cell viability, cancer stem cells and stemness marker mRNA expression, as well as inflammation-related signature profile expression and its prognosis in primary- and metastatic-derived colorectal tumourspheres derived from colorectal cell lines isolated from the same patient 1 year apart. The results indicate that primary-derived colorectal tumourspheres respond to oxaliplatin, adapting to the adverse conditions through the modulation of CSCs and the stemness properties of tumourspheres. However, metastatic-derived colorectal tumourspheres response led to the release of cytokines and chemokines, promoting an inflammatory process. In addition, the expression of inflammatory markers showing greater difference between primary and metastatic tumours after oxaliplatin treatment correlates with poor prognosis in KM survival studies and is associated with a metastatic phenotype. Our data demonstrated that oxaliplatin triggers an inflammation-related signature profile expression in primary-derived colorectal tumourspheres, related with poor prognosis and a metastatic phenotype, which allow the tumour cells to adapt to the adverse condition. These data highlight the need for of drug testing and personalized medicine in the early stages of colorectal cancer.Multidisciplinary Digital Publishing Institute (MDPI)20242024-10-0920232023-02-1420232023-02-14research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/23691reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/236912026-06-12T12:43:37Z
dc.title.none.fl_str_mv Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
title Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
spellingShingle Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
Martinez-Bernabe, Toni
Neoplasias Colorrectales
Humanos
Citocinas
Protocolos de Quimioterapia Combinada Antineoplásica
Oxaliplatino
Cytokines
Colorectal Neoplasms
Humans
Oxaliplatin
Antineoplastic Combined Chemotherapy Protocols
title_short Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
title_full Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
title_fullStr Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
title_full_unstemmed Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
title_sort Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer
dc.creator.none.fl_str_mv Martinez-Bernabe, Toni
Oliver, Jordi
Sastre-Serra, Jorge
Pons, Daniel-Gabriel
author Martinez-Bernabe, Toni
author_facet Martinez-Bernabe, Toni
Oliver, Jordi
Sastre-Serra, Jorge
Pons, Daniel-Gabriel
author_role author
author2 Oliver, Jordi
Sastre-Serra, Jorge
Pons, Daniel-Gabriel
author2_role author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Neoplasias Colorrectales
Humanos
Citocinas
Protocolos de Quimioterapia Combinada Antineoplásica
Oxaliplatino
Cytokines
Colorectal Neoplasms
Humans
Oxaliplatin
Antineoplastic Combined Chemotherapy Protocols
topic Neoplasias Colorrectales
Humanos
Citocinas
Protocolos de Quimioterapia Combinada Antineoplásica
Oxaliplatino
Cytokines
Colorectal Neoplasms
Humans
Oxaliplatin
Antineoplastic Combined Chemotherapy Protocols
description Oxaliplatin is successfully used to eradicate micro-metastasis and improve survival, whereas the benefit of adjuvant chemotherapy in the early stages of colorectal cancer remains controversial. Inflammation plays a crucial role in colorectal cancer tumorigenesis. Inflammatory mechanisms are mediated by different immune cells through different cytokines, chemokines, and other proinflammatory molecules that trigger cell progression, an increase of cancer stem cell population, hyperplasia, and metastasis. This study focuses on the analysis of the oxaliplatin effect on tumourspheres formation efficiency, cell viability, cancer stem cells and stemness marker mRNA expression, as well as inflammation-related signature profile expression and its prognosis in primary- and metastatic-derived colorectal tumourspheres derived from colorectal cell lines isolated from the same patient 1 year apart. The results indicate that primary-derived colorectal tumourspheres respond to oxaliplatin, adapting to the adverse conditions through the modulation of CSCs and the stemness properties of tumourspheres. However, metastatic-derived colorectal tumourspheres response led to the release of cytokines and chemokines, promoting an inflammatory process. In addition, the expression of inflammatory markers showing greater difference between primary and metastatic tumours after oxaliplatin treatment correlates with poor prognosis in KM survival studies and is associated with a metastatic phenotype. Our data demonstrated that oxaliplatin triggers an inflammation-related signature profile expression in primary-derived colorectal tumourspheres, related with poor prognosis and a metastatic phenotype, which allow the tumour cells to adapt to the adverse condition. These data highlight the need for of drug testing and personalized medicine in the early stages of colorectal cancer.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-02-14
2023
2023-02-14
2024
2024-10-09
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/23691
url https://hdl.handle.net/20.500.12105/23691
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414926954528768
score 15,812429

Registros relacionados